EDMONTON, Alberta, June 21, 2018 /PRNewswire/ --
First G7 Country to Legalize Adult
Consumer Use - Sales to Commence October 17
TSX: ACB
Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB)
(OTCQB: ACBFF) (Frankfurt: 21P;
WKN: A1C4WM) commented today on the granting of Royal Assent to
Bill C-45, the Cannabis Act. With Royal Assent
received, the legislation legalizing cannabis for adult consumer
use has now passed its final official step, and retail sales are to
commence October 17, 2018, as
announced by Canada's federal
government yesterday.
"The granting of Royal Assent today ends nearly a century of
cannabis prohibition, marking a truly historic moment for all
Canada, for Canadian public
policy, and for this country's cannabis sector," said Terry Booth, CEO. "International delegates have
been coming to Canada for years to
study our medical cannabis system, which is globally renowned for
its efficiency and success. Canada's legal framework is increasingly
serving as a model for other countries looking to implement their
own medical cannabis legislation. With the Cannabis
Act, Canada further establishes its global leadership as
the only G7 country to legalize adult consumer use. The federal
government has provided intelligent and rational public policy
focused on clearly defined objectives that will reduce the negative
impact of prohibition, while establishing a well-regulated system
designed to protect youth, public health and public safety. Aurora
is proud to be a leader in this new industry, both as a producer of
high-quality cannabis, and as an advocate for fairness and justice,
including amnesty on past non-violent cannabis-related offenses,
and on achieving tax-exempt status for medical cannabis."
Mr. Booth continued, "Aurora is executing on a broad, deep and
innovative consumer market strategy, supported by massive
production, extensive distribution channels and strong brands. With
production at our facilities, including Aurora Sky, ramping up very
rapidly, we look forward to provide this large and exciting market
with an excellent portfolio of Aurora
Standard products, ensuring unique user experiences to a new
group of customers from October 17,
2018 onwards."
About Aurora
Headquartered in Edmonton,
Alberta, with funded capacity in excess of 430,000 kg per
year and operations across Canada
and in Europe, Aurora is one of
the world's largest cannabis companies. The Company is vertically
integrated and horizontally diversified across every key segment of
the value chain, from facility design and engineering, to cannabis
breeding and genetics research, cannabis and hemp production,
extraction and high value-add product development, home cultivation
and wholesale and retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes. Intended to be replicable and
scalable globally, these production facilities are designed to
produce cannabis on a massive scale, with high flower quality,
industry-leading yields, and ultra-low per gram production costs.
Each of the Company's facilities is built to meet European Union
(EU) GMP standards, and both its first production facility and its
wholly owned European medical cannabis distributor Pedanios have
achieved that level of certification.
In addition to its rapid organic growth and strategic M&A,
which to date includes nine companies acquired, Aurora is
distinguished by its reputation as a partner of choice in the
cannabis sector, having invested in and established strategic
partnerships with a range of leading innovators, including: The
Green Organic Dutchman Holdings Ltd. (TSX: TGOD), Radient
Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV:
HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc.
(CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Namaste Technologies
Inc. (TSXV: N), and Alcanna Inc. (TSX: CLIQ).
Aurora's Common Shares trade on the TSX under the symbol "ACB",
and are a constituent of the S&P/TSX Composite Index.
For more information about Aurora, please visit our investor
website investor.auroramj.com .
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. These statements are only predictions.
Various assumptions were used in drawing the conclusions or making
the projections contained in the forward-looking statements
throughout this news release. Forward-looking statements are based
on the opinions and estimates of management at the date the
statements are made, and are subject to a variety of risks and
uncertainties and other factors that could cause actual events or
results to differ materially from those projected in the
forward-looking statements. The Company is under no obligation, and
expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable law.
Neither TSX nor its Regulation Services Provider (as that
term is defined in the policies of Toronto Stock Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
Terry Booth, CEO
Aurora Cannabis Inc.
For Aurora: Marc Lakmaaker, +1-647-269-5523,
marc.lakmaaker@auroramj.com, http://www.auroramj.com; Rob Kelly, +1-647-331-7228,
rob.kelly@auroramj.com, http://www.auroramj.com ; U.S. investors:
Phil Carlson / Elizabeth Barker, KCSA Strategic Communications,
Phone: (212)-896-1233, (212)-896-1203,
Email: pcarlson@kcsa.com / ebarker@kcsa.com